$0.04
(Market cap
$1 Mln
Recently Viewed
Clear AllMarket cap
$1 Mln
Revenue (TTM)
$-14 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-13 Mln
ROE
-1.9 %
ROCE
-- %
Industry P/E
46.76
EV/EBITDA
-0.3
Debt to Equity
0
Book Value
$--
EPS
$-6
Face value
--
Shares outstanding
2,626,030
CFO
$-146.10 Mln
EBITDA
$-166.06 Mln
Net Profit
$-183.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biocept (BIOC)
| -99.6 | 55.1 | -95.2 | -99.6 | -92.1 | -80.6 | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Biocept (BIOC)
| -99.6 | -85.4 | -18.5 | 55.2 | -66.7 | -95.8 | -10.5 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biocept (BIOC)
|
0.1 | 1.1 | -14.4 | -46.2 | 209.8 | -1009.6 | -- | 0.4 |
| 7.9 | 5,292.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 299.5 | 8,082.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10.8 | 1.1 | |
| 36.6 | 5,563.8 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.2 | |
| 121.5 | 7,074.2 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.8 | |
| 84.3 | 5,490.1 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.7 | 5.0 | |
| 178.6 | 9,353.6 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.8 | 13.0 | |
| 329.9 | 13,067.9 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73.7 | 9.1 | |
| 117.6 | 6,632.6 | 738.3 | 48.9 | 11.4 | 2.4 | 136.7 | 3.2 | |
| 31.6 | 13,623.0 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.3 | 2.6 |
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the... United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Interim Pres, CEO & Chairman
Mr. Samuel D. Riccitelli
Interim Pres, CEO & Chairman
Mr. Samuel D. Riccitelli
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Biocept Inc (BIOC) is $0.07 (NASDAQ) as of 26-Dec-2023 09:30 EDT. Biocept Inc (BIOC) has given a return of -92.09% in the last 3 years.
Since, TTM earnings of Biocept Inc (BIOC) is negative, P/E ratio is not available.
The P/B ratio of Biocept Inc (BIOC) is 0.37 times as on 26-Dec-2023, a 89 discount to its peers’ median range of 3.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.28
|
1.02
|
|
2021
|
-21.60
|
1.63
|
|
2020
|
-0.12
|
0.08
|
|
2019
|
0.00
|
0.00
|
|
2018
|
0.00
|
0.00
|
The 52-week high and low of Biocept Inc (BIOC) are Rs -- and Rs -- as of 27-Apr-2026.
Biocept Inc (BIOC) has a market capitalisation of $ 1 Mln as on 26-Dec-2023. As per SEBI classification, it is a company.
Before investing in Biocept Inc (BIOC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.